Cargando…

Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications

MF59(®)-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent inactivated influenza vaccine (HD-IIV3) elicit an enhanced immune response in older adults compared to standard, quadrivalent inactivated influenza vaccines (IIV4). We sought to determine the relative vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boikos, Constantina, Imran, Mahrukh, Nguyen, Van Hung, Ducruet, Thierry, Sylvester, Gregg C., Mansi, James A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402367/ https://www.ncbi.nlm.nih.gov/pubmed/34451987 http://dx.doi.org/10.3390/vaccines9080862

Ejemplares similares

Effectiveness of the Cell-Derived Inactivated Quadrivalent Influenza Vaccine in Individuals at High Risk of Influenza Complications in the 2018–2019 United States Influenza Season
por: Boikos, Constantina, et al.
Publicado: (2021)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018
por: Boikos, Constantina, et al.
Publicado: (2020)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
por: Boikos, Constantina, et al.
Publicado: (2021)

Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research
por: Boikos, Constantina, et al.
Publicado: (2022)

Relative Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Adults During the 2019–2020 Influenza Season in the United States
por: Imran, Mahrukh, et al.
Publicado: (2022)

Relative Effectiveness of Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children and Adolescents in the United States During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
por: Boikos, Constantina, et al.
Publicado: (2022)

Understanding the Impact of Approved but Unfunded Vaccine Status on Parental Acceptance of an Adjuvanted Seasonal Influenza Vaccine for Infants: Results from the Pediatric Influenza Vaccination Optimization Trial (PIVOT)–III
por: Fisher, William A., et al.
Publicado: (2022)

Parental Attitudes and Perceptions of Support after Brief Clinician Intervention Predict Intentions to Accept the Adjuvanted Seasonal Influenza Vaccination: Findings from the Pediatric Influenza Vaccination Optimization Trial (PIVOT)–I
por: Fisher, William A., et al.
Publicado: (2022)

Achieving Influenza Vaccine Uptake Target in Canada via a Pharmacy-Led Telephone Discussion during the 2019–2020 Season
por: Strain, William David, et al.
Publicado: (2021)

Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
por: Rajaram, Sankarasubramanian, et al.
Publicado: (2020)

Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2022)

LB-2. Relative Effectiveness of aIIV3 versus IIV4 and HD-IIV3 In Preventing Influenza-Related Medical Encounters in Adults ≥65 Years of Age at High Risk for Influenza Complications During the U.S. 2017–2018 and 2018–2019 Influenza Seasons
por: Fischer, Lauren, et al.
Publicado: (2020)

Clinicians Are Not Able to Infer Parental Intentions to Vaccinate Infants with a Seasonal Influenza Vaccine, and Perhaps They Should Not Try: Findings from the Pediatric Influenza Vaccination Optimization Trial (PIVOT)–IV
por: Fisher, William A., et al.
Publicado: (2022)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

2470. The Effect of Information–Motivation–Behavioral Skills Model-Based Continuing Medical Education on Pediatric Influenza Immunization Uptake: A Randomized, Controlled Trial
por: Fisher, William, et al.
Publicado: (2018)

Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings
por: Boikos, Constantina, et al.
Publicado: (2016)

Continuing Medical Education Improves Physician Communication Skills and Increases Likelihood of Pediatric Vaccination: Findings from the Pediatric Influenza Vaccination Optimization Trial (PIVOT)—II
por: Fisher, William A., et al.
Publicado: (2022)

Impact of General Practitioner Education on Acceptance of an Adjuvanted Seasonal Influenza Vaccine among Older Adults in England
por: de Lusignan, Simon, et al.
Publicado: (2023)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
por: Lu, Lu, et al.
Publicado: (2020)

Adjuvanted influenza vaccine dynamics
por: Parra-Rojas, César, et al.
Publicado: (2019)

Advances in Adjuvanted Influenza Vaccines
por: Shichinohe, Shintaro, et al.
Publicado: (2023)

T Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults
por: Haralambieva, Iana H., et al.
Publicado: (2022)

ADJUVANTS IN IMMUNIZATION WITH INFLUENZA VIRUS VACCINES
por: Friedewald, William F.
Publicado: (1944)

The Impact of Adjuvanted Influenza Vaccine on Disease Severity in the US: A Stochastic Model
por: Pelton, Stephen I., et al.
Publicado: (2023)

Relative Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine in Preventing Cardiorespiratory Hospitalizations in Adults Aged 18–64 Years During the 2019–2020 US Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2023)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

Near-Infrared Laser Adjuvant for Influenza Vaccine
por: Kashiwagi, Satoshi, et al.
Publicado: (2013)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

Improving seasonal influenza vaccination for older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Injectable Excipients as Novel Influenza Vaccine Adjuvants
por: Feng, Huapeng, et al.
Publicado: (2019)

Food Additives as Novel Influenza Vaccine Adjuvants
por: Feng, Huapeng, et al.
Publicado: (2019)

Promising Adjuvants and Platforms for Influenza Vaccine Development
por: Zhu, Wandi, et al.
Publicado: (2021)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rvsqh0sdo4qsc2kt5mh4sj9bdp